SAMH
TVTX icon

Shanda Asset Management Holdings’s Travere Therapeutics TVTX Stock Holding History

Shanda Asset Management Holdings’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-25,342
Closed -$517K – 99
2020
Q2 		$517K Buy
+25,342
New +$404K 0.05% 73

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Shanda Asset Management Holdings's TVTX Position: Q3 2020 in Review

Shanda Asset Management Holdings sold out of Travere Therapeutics (TVTX) in Q3 2020, closing a stake of 25,342 shares — an estimated $517K sold.

Shanda Asset Management Holdings first reported a position in TVTX in Q2 2020 and held it in 1 quarter. The position peaked at $517K in Q2 2020. 134 funds tracked by Wall St. Rank hold TVTX as of Q3 2020.

  • Shanda Asset Management Holdings reported no remaining Travere Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Shanda Asset Management Holdings sold 25,342 Travere Therapeutics shares in Q3 2020, an estimated $517K.
  • Shanda Asset Management Holdings first reported a position in Travere Therapeutics in Q2 2020 and held it in 1 quarter.
  • Shanda Asset Management Holdings's Travere Therapeutics position peaked at $517K in Q2 2020.
  • 134 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2020.

Based on Shanda Asset Management Holdings's 13F filing for Q3 2020, filed 16 Nov 2020.